BMS sees success in Phase III Sotyktu psoriatic arthritis trials
Bristol Myers Squibb (BMS) has announced positive topline results from two Phase III trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA), with both trials hitting their endpoints. In both …